Company intelligence / Profile preview

Aralez

San Leandro, California, United Statesaralezbio.com ↗

Ownership: Private
Development stage: Commercial

Overview

Aralez Bio has developed an industry-leading enzymatic platform to manufacture noncanonical amino acids with high yield and purity. The company is scaling up to commercial production capacity to support pharmaceutical partners—including top five global pharma companies—in developing next-generation peptide drugs and other therapeutics that require ncAAs. The company recently closed a $12 million Series A round to accelerate commercialization.

Therapeutic areas: Metabolic Disorders
Modalities: Small moleculePeptidesEnzymatically produced amino acid analogs
Industry: Chemicals & Materials

Partnerships

National Resilience Inc. (federal Defense Product Act award partnership)Top five global pharmaceutical companies as customers/clients [implied by press release].

Beyond the preview

Go deeper on Aralez.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aralez.

Explore the full profile